Physician profile
Jason A Krystofiak
NPI 1679991145
$31,279.13
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 98% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $122 · 2021: $190 · 2022: $64.46 · 2023: $13K · 2024: $4,784 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $4,394 · Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,532.11 |
| Travel and Lodging | $4,394.31 |
| Food and Beverage | $1,036.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $28,659.38 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $716.60 | 2023 | Iovera |
| Bioventus LLC | $294.71 | 2020-2025 | Xcell, Durolane, Durolane |
| Novo Nordisk INC | $258.93 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $234.59 | 2019-2025 | Euflexxa |
| Astrazeneca Pharmaceuticals Lp | $217.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $101.29 | 2019 | |
| Avanos Medical | $80.56 | 2023-2025 | Trivisc Sodium Hyaluronate |
| Depuy Synthes Sales INC. | $64.63 | 2023-2025 | Monovisc, Orthovisc |
| Merz Pharmaceuticals, LLC | $58.33 | 2023 | Xeomin |
| Pacira Therapeutics, INC. | $56.54 | 2020-2021 | |
| Pfizer INC. | $55.54 | 2019 | |
| Abbvie INC. | $50.23 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.13 | 2019 | |
| Amgen INC. | $37.13 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.99 | 2019 | |
| Ibsa Pharma INC. | $35.00 | 2024-2025 | Tirosint, Licart, Flector |
| Fidia Pharma USA INC. | $31.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.45 | 2019 | |
| Lilly USA, LLC | $27.56 | 2019 | |
| Amarin Pharma, INC. | $26.93 | 2019 | |
| Horizon Therapeutics Plc | $25.02 | 2020-2021 | |
| Vivus LLC | $24.16 | 2019 | |
| Merck Sharp & Dohme LLC | $24.14 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.36 | 2025 | Horizant |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| Abbott Laboratories | $13.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2019 | |
| Bausch Health US, LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Krystofiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.